GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update

Posted by Defense World Staff on Feb 19th, 2025

GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 2,030,000 shares, a drop of 9.4% from the January 15th total of 2,240,000 shares. Based on an average daily volume of 890,600 shares, the short-interest ratio is presently 2.3 days.

Institutional Trading of GlycoMimetics

Institutional investors have recently bought and sold shares of the business. Caxton Corp acquired a new stake in GlycoMimetics during the 4th quarter worth $51,000. ADAR1 Capital Management LLC grew its holdings in GlycoMimetics by 626.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 286,127 shares during the period. Jefferies Financial Group Inc. acquired a new stake in GlycoMimetics during the 4th quarter worth $106,000. Wellington Management Group LLP bought a new position in shares of GlycoMimetics during the fourth quarter worth $352,000. Finally, VR Adviser LLC bought a new position in shares of GlycoMimetics during the fourth quarter worth $747,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of GlycoMimetics in a report on Tuesday. They issued a “sell” rating for the company.

Read Our Latest Research Report on GLYC

GlycoMimetics Price Performance

Shares of GlycoMimetics stock opened at $0.36 on Wednesday. The firm has a 50 day simple moving average of $0.26 and a 200 day simple moving average of $0.24. GlycoMimetics has a fifty-two week low of $0.14 and a fifty-two week high of $3.36.

GlycoMimetics (NASDAQ:GLYC – Get Free Report) last released its earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05.

About GlycoMimetics

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.